ClinicalTrials.gg
WithdrawnNCT05070650Updated Sep 26, 2024

Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold

A Phase 3 interventional study of Acetylcysteine and Paracetamol in Common Cold, sponsored by Sandoz. Withdrawn. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-09-26.

Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Sandoz has decided to withdraw the clinical study due to internal business reasons. No patients were enrolled in any of the participating countries.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Prospective, randomized, multinational, multicenter, double-blind trial in 2 parallel groups of patients

Read the detailed description

This study is a prospective, randomized, multinational, multicenter, double-blind trial in 2 parallel groups of patients.

Patients will undergo screening examinations at Visit 1.

Patients who meet all of the inclusion and none of the exclusion criteria will be randomized to double-blind treatment with one of the following:

  • Group A: Acetylcysteine/Paracetamol/Phenylephrine: one sachet three times per day OR
  • Group B: Paracetamol/Phenylephrine 500 mg/10 mg granules for oral solution: one sachet three times per day.

A control visit (Visit 2) is planned on Day 3 of treatment.

After the end of the double-blind treatment phase, the patients will undergo an end-of-treatment (EOT) examination at Visit 3 on Day 6.

02

Conditions studied

  • Common Cold

Browse trials for

03

In context

Common Cold

219 studies on the registry are indexed under Common Cold; 23 are open to participants now.

Browse Common Cold studies →

Lead sponsor

Sandoz is the lead sponsor of 139 studies on the registry; none are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.

First submitted before Sandoz left Novartis.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged between 18 and 75 years inclusive on the date of consent
  2. No fever or (mild) fever below 38.5° C
  3. Total score (sum of all ratings) of 2 or higher based on the rating of the following symptoms of common cold (Jackson scale):

    1. Sneezing
    2. Nasal discharge
    3. Nasal obstruction
    4. Sore throat
    5. Cough
    6. Headache
    7. Malaise
    8. Chilliness according to the following rating scale: 0 = absent, 1 = mild, 2 = moderate, or 3 = severe
  4. Presence of cough with thick mucus production
  5. to participate in the trial provided in written form

Exclusion criteria

Exclusion Criteria:

  1. Duration of any of the symptoms of common cold of more than 72 hours at the time of screening
  2. History of or intolerance to the active substances or any of the of the trial medication
  3. Known bronchial asthma or
  4. Known duodenal or gastric ulcer
  5. Known hyperthyroidism
  6. Known narrow angle glaucoma
  7. Known pheochromocytoma
  8. Known prostate adenoma with urine retention
  9. Known severe liver failure ( > 9)
  10. Known severe cardio-vascular diseases
  11. Known porphyria
  12. Known glucose-6-phosphate dehydrogenase deficiency
  13. High fever (body temperature above 38.5°C)
  14. Intake of antibiotics, , immuno-stimulating or immuno-modulating medication, within 30 days prior to screening visit
  15. Intranasal or systemic use of within 30 days prior to screening visit
  16. Intake of antihistamines or nasal decongestants within 48 hours prior to screening visit
  17. Vaccination within 14 days prior to screening visit
  18. Immunocompromised state
  19. Suspicion for acute bacterial infection
  20. Pregnant or breast-feeding female patient
  21. Female patient of (not surgically sterilized/ hysterectomized or for at least 1 year) who is not currently using (documented at screening visit) and not willing to use medically reliable methods of for the entire trial duration such as barrier method, oral, injectable or implantable contraceptives, intrauterine contraceptive devices (IUD), sexual abstinence or vasectomized partner
  22. Any other condition of the patient (e.g. serious or unstable medical or psychological condition, acute psychosis) that in the opinion of the investigator may compromise evaluation of the trial treatment or may jeopardize patient's safety, compliance or adherence to protocol requirements
  23. Participation in ANY research study involving another medicinal product (IMP) within 30 days prior to screening visit, or simultaneous participation in another clinical study or previous participation in present study
  24. Suspected alcohol/ drug dependence or abuse (including heavy smoking: ≥ 20 cigarettes daily)
  25. Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequences of the trial
  26. Subjects who are known or suspected:

    • not to comply with the trial directives
    • not to be reliable or trustworthy
    • to be a dependent person, e.g. a relative, family member, or member/ employee of the investigator's or sponsor's staff
    • subject is in custody or submitted to an institution due to a judicial order.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Acetylcysteine/Paracetamol/Phenylephrine 200 mg/500 mg/10 mg granules for oral solution

    Acetylcysteine/Paracetamol/Phenylephrine 200 mg/500 mg/10 mg granules for oral solution: one sachet three times per day

    Drug: Acetylcysteine · Drug: Paracetamol · Drug: Phenylephrine

  • Active comparator
    Paracetamol/Phenylephrine 500 mg/10 mg granules for oral solution

    Paracetamol/Phenylephrine 500 mg/10 mg granules for oral solution: one sachet three times per day

    Drug: Paracetamol · Drug: Phenylephrine

Interventions

  • 200 mg/500 mg/10 mg granules for oral solution: one sachet three times per day

  • 500 mg/10 mg granules for oral solution: one sachet three times per day

  • 500 mg/10 mg granules for oral solution

06

What researchers measure

Primary outcomes

  1. Change from baseline in the daily Score of 8 symptoms related to mucus production (SUM8)

    Score of 8 symptoms related to mucus production (SUM8) will be assessed by the patient in a patient's diary at screening (this will constitute the baseline value) and daily on each day of treatment until and including Day 5. For assessing SUM8 the patients will have to answer questions about their cough and phlegm status. The SUM8 consisted of the sum of the answers to the eight core questions. For calculating the SUM8 the lowest rating corresponds to 0 and highest rating corresponds to 4, with 4 representing the greatest severity of symptoms. The SUM8 thus had a scale range of 0-32 with 0 representing best possible symptoms, and 32 representing greatest severity of symptoms.

    Time frame: Baseline, Day 5

Secondary outcomes

  1. Number of adverse events and serious adverse events

    Assessment of safety and tolerability of the investigational medicinal product against the comparator product for the treatment of common cold

    Time frame: Until Day 6, or earlier in case of premature termination

  2. Time to onset of action

    Time to onset of action defined as first day of treatment with investigational product on which SUM8 shows statistically significant difference from the comparator product will be reported

    Time frame: Day 1 to Day 5

  3. Score of 8 symptoms related to mucus production (SUM8) development over the course of the study

    Score of 8 symptoms related to mucus production (SUM8) will be assessed by the patient in a patient's diary at screening (this will constitute the baseline value) and daily on each day of treatment until and including Day 5. For assessing SUM8 the patients will have to answer questions about their cough and phlegm status. The SUM8 consisted of the sum of the answers to the eight core questions. For calculating the SUM8 the lowest rating corresponds to 0 and highest rating corresponds to 4, with 4 representing the greatest severity of symptoms. The SUM8 thus had a scale range of 0-32 with 0 representing best possible symptoms, and 32 representing greatest severity of symptoms.

    Time frame: Baseline, Day 1 to Day 5

  4. Assessment of separate items of Score of 8 symptoms related to mucus production (SUM8)

    Score of 8 symptoms related to mucus production (SUM8) will be assessed by the patient in a patient's diary at screening (this will constitute the baseline value) and daily on each day of treatment until and including Day 5. For assessing SUM8 the patients will have to answer questions about their cough and phlegm status. The SUM8 consisted of the sum of the answers to the eight core questions. For calculating the SUM8 the lowest rating corresponds to 0 and highest rating corresponds to 4, with 4 representing the greatest severity of symptoms. The SUM8 thus had a scale range of 0-32 with 0 representing best possible symptoms, and 32 representing greatest severity of symptoms.

    Time frame: Baseline, Day 1 to Day 5

  5. Sum of changes from baseline in the daily Wisconsin Upper Respiratory Symptom Survey (WURSS-21)

    The Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Questionnaire is an evaluative illness-specific outcomes instrument designed to assess the severity of cold symptoms and the impact of the common cold (range 0-140), with higher scores indicating more symptoms and functional impairment.

    Time frame: Baseline, Day 1 to Day 5

  6. Assessment of separate items of Wisconsin Upper Respiratory Symptom Survey (WURSS-21)

    The Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Questionnaire is an evaluative illness-specific outcomes instrument designed to assess the severity of cold symptoms and the impact of the common cold (range 0-140), with higher scores indicating more symptoms and functional impairment.

    Time frame: Baseline, Day 1 to Day 5

  7. Percentage of responders and non-responders to treatment

    Percentage of responders and non-responders to treatment based on the assessment of overall response to treatment by the investigator will be reported.

    Time frame: On Day 3, and after the end of treatment on Day 6

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2024; primary completion for Apr 2025, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2021
First posted
Oct 7, 2021
StartEst.
Sep 20, 2024
Primary completionEst.
Apr 30, 2025
CompletionEst.
Apr 30, 2025
Last update
Sep 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05070650
Lead sponsor
Sandoz
Responsible party
Sponsor
First posted
Oct 7, 2021
Start date
Sep 20, 2024 (estimated)
Primary completion
Apr 30, 2025 (estimated)
Completion
Apr 30, 2025 (estimated)
Last update
Sep 26, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetylcysteine

Start the discussion